Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Sondel, Paul M ^a,b   Alderson, Kory L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CHIMERIC MONOCLONAL ANTIBODY CH14.18; FC RECEPTOR; FC RECEPTOR IIIA; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; ISOTRETINOIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; CANCER ANTIBODY; CYTOKINE; CYTOKINE RECEPTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DNA POLYMORPHISM; EVENT FREE SURVIVAL; GENOTYPE; HIGH RISK PATIENT; HUMAN; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUROBLASTOMA; NONHUMAN; REVIEW; TREATMENT RESPONSE; TUMOR CELL; CELLULAR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; RECEPTORS, CYTOKINE; RECEPTORS, FC; RECEPTORS, KIR;

EID: 80052658231     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/379123     Document Type: Review

References (58)

1. Orange J. S., Human natural killer cell deficiencies and susceptibility to infection Microbes and Infection 2002 4 15 1545 1558 (Pubitemid 36050824)
2. Trapani J. A., Voskoboinik I., Infective, neoplastic, and homeostatic sequelae of the loss of perforin function in humans Advances in experimental medicine and biology 2007 601 235 242
3. Ravetch J. V., Bolland S., IgG Fc receptors Annual Review of Immunology 2001 19 275 290 (Pubitemid 32368037)
4. Sondel P. M., Hank J. A., Antibody-directed, effector cell-mediated tumor destruction Hematology/Oncology Clinics of North America 2001 15 4 703 721 (Pubitemid 32959256)
5. Navid F., Santana V. M., Barfield R. C., Anti-GD2 antibody therapy for GD2-expressing tumors Current Cancer Drug Targets 2010 10 2 200 209
6. Garnock-Jones K. P., Keating G. M., Scott L. J., Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer Drugs 2010 70 2 215 239
7. Garca-Foncillas J., Daz-Rubio E., Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome Clinical and Translational Oncology 2010 12 8 533 542
8. Winter M. C., Hancock B. W., Ten years of rituximab in NHL Expert Opinion on Drug Safety 2009 8 2 223 235
9. Albertini M. R., Hank J. A., Sondel P. M., Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma Cancer Chemotherapy and Biological Response Modifiers 2005 22 789 797
10. Yang R. K., Sondel P. M., Anti-GD2 strategy in the treatment of neuroblastoma Drugs Future 2010 35 8 665
11. Nimmerjahn F., Ravetch J. V., Fc receptors as regulators of immune responses Nature Reviews Immunology 2008 8 1 34 47
12. Delgado D. C., Hank J. A., Kolesar J., Lorentzen D., Gan J., Seo S., Kim K., Shusterman S., Gillies S. D., Reisfeld R. A., Yang R., Gadbaw B., DeSantes K. B., London W. B., Seeger R. C., Maris J. M., Sondel P. M., Genotypes of NK cell KIR receptors, their ligands, and Fc receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy Cancer Research 2010 70 23 9554 9561
13. Beano A., Signorino E., Evangelista A., Brusa D., Mistrangelo M., Polimeni M. A., Spadi R., Donadio M., Ciuffreda L., Matera L., Correlation between NK function and response to trastuzumab in metastatic breast cancer patients Journal of Translational Medicine 2008 6, article no. 25
14. Hank J. A., Weil-Hillman G., Surfus J. E., Sosman J. A., Sondel P. M., Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo Cancer Immunology Immunotherapy 1990 31 1 53 59 (Pubitemid 20045589)
15. Ortaldo J. R., Woodhouse C., Morgan A. C., Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies Journal of Immunology 1987 138 10 3566 3572 (Pubitemid 17071947)
16. Van Ojik H. H., Bevaart L., Dahle C. E., Bakker A., Jansen M. J. H., Van Vugt M. J., Van de Winkel J. G. J., Weiner G. J., CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations Cancer Research 2003 63 17 5595 5600 (Pubitemid 37139883)
17. Betting D. J., Yamada R. E., Kafi K., Said J., Van Rooijen N., Timmerman J. M., Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B Cell lymphoma Journal of Immunotherapy 2009 32 6 622 631
18. Kohrt H. E., Houot R., Goldstein M. J., Weiskopf K., Alizadeh A. A., Brody J., Mller A., Pachynski R., Czerwinski D., Coutre S., Chao M. P., Chen L., Tedder T. F., Levy R., CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies Blood 2011 117 8 2423 2432
19. Bowles J. A., Wang S. Y., Link B. K., Allan B., Beuerlein G., Campbell M. A., Marquis D., Ondek B., Wooldridge J. E., Smith B. J., Breitmeyer J. B., Weiner G. J., Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab Blood 2006 108 8 2648 2654
20. Weiner L. M., Surana R., Wang S., Monoclonal antibodies: versatile platforms for cancer immunotherapy Nature Reviews Immunology 2010 10 5 317 327
21. Lin W., Voskens C. J., Zhang X., Schindler D. G., Wood A., Burch E., Wei Y., Chen L., Tian G., Tamada K., Wang L. X., Schulze D. H., Mann D., Strome S. E., Fc-dependent expression of CD137 on human NK cells: insights into agonistic effects of anti-CD137 monoclonal antibodies Blood 2008 112 3 699 707
22. Parihar R., Dierksheide J., Hu Y., Carson W. E., IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells Journal of Clinical Investigation 2002 110 7 983 992
23. Parihar R., Nadella P., Lewis A., Jensen R., De Hoff C., Dierksheide J. E., VanBuskirk A. M., Magro C. M., Young D. C., Shapiro C. L., Carson III W. E., A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon production in a subset of patients Clinical Cancer Research 2004 10 15 5027 5037 (Pubitemid 39099777)
24. Schultz K. R., Klarnet J. P., Peace D. J., Cheever M. A., Badger C. C., Bernstein I. D., Greenberg P. D., Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells Cancer Research 1990 50 17 5421 5425 (Pubitemid 20302998)
25. Watanabe M., Kubota T., Kitajima M., Hakomori S., Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice Cancer Immunology Immunotherapy 1993 37 4 245 250 (Pubitemid 23300505)
26. Helfand S. C., Soergel S. A., Donner R. L., Gan J., Hank J. A., Lindstrom M. J., Sondel P. M., Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model Journal of Immunotherapy 1994 16 3 188 197 (Pubitemid 24321451)
27. Neal Z. C., Yang J. C., Rakhmilevich A. L., Buhtoiarov I. N., Lum H. E., Imboden M., Hank J. A., Lode H. N., Reisfeld R. A., Gillies S. D., Sondel P. M., Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy Clinical Cancer Research 2004 10 14 4839 4847 (Pubitemid 38955538)
28. Iida S., Kuni-Kamochi R., Mori K., Misaka H., Inoue M., Okazaki A., Shitara K., Satoh M., Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood BMC Cancer 2009 9, article no. 58
29. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., Shitara K., The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity Journal of Biological Chemistry 2003 278 5 3466 3473 (Pubitemid 36801263)
30. Sorkin L. S., Otto M., Baldwin W. M., Vail E., Gillies S. D., Handgretinger R., Barfield R. C., Ming Yu H., Yu A. L., Anti-GD with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia Pain 2010 149 1 135 142
31. Gillies S. D., Young D., Lo K. M., Roberts S., Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins Bioconjugate Chemistry 1993 4 3 230 235
32. Hank J. A., Surfus J. E., Gan J., Jaeger P., Gillies S. D., Reisfeld R. A., Sondel P. M., Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD interleukin-2 fusion protein (ch14.18-IL2) Clinical Cancer Research 1996 2 12 1951 1959 (Pubitemid 27006627)
33. Yamane B. H., Hank J. A., Albertini M. R., Sondel P. M., The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma Expert Opinion on Investigational Drugs 2009 18 7 991 1000
34. Johnson E. E., Lum H. D., Rakhmilevich A. L., Schmidt B. E., Furlong M., Buhtoiarov I. N., Hank J. A., Raubitschek A., Colcher D., Reisfeld R. A., Gillies S. D., Sondel P. M., Intratumoral immunocytokine treatment results in enhanced antitumor effects Cancer Immunology, Immunotherapy 2008 57 12 1891 1902
35. Lode H. N., Xiang R., Varki N. M., Dolman C. S., Gillies S. D., Reisfeld R. A., Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow Journal of the National Cancer Institute 1997 89 21 1586 1594 (Pubitemid 27479718)
36. Buhtoiarov I. N., Neal Z. C., Gan J., Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting Journal of Leukocyte Biology 2011 89 4 625 638
37. Gubbels J. A. A., Gadbaw B., Buhtoiarov I. N., Ab-IL2 fusion protein mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunology and Immunotherapy. Manuscript Submitted
38. Maris J. M., Recent advances in neuroblastoma New England Journal of Medicine 2010 362 23 2154 2211
39. Yu A. L., Gilman A. L., Ozkaynak M. F., London W. B., Kreissman S. G., Chen H. X., Smith M., Anderson B., Villablanca J. G., Matthay K. K., Shimada H., Grupp S. A., Seeger R., Reynolds C. P., Buxton A., Reisfeld R. A., Gillies S. D., Cohn S. L., Maris J. M., Sondel P. M., Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma New England Journal of Medicine 2010 363 14 1324 1334
40. Shusterman S., London W. B., Gillies S. D., Hank J. A., Voss S. D., Seeger R. C., Reynolds C. P., Kimball J., Albertini M. R., Wagner B., Gan J., Eickhoff J., DeSantes K. B., Cohn S. L., Hecht T., Gadbaw B., Reisfeld R. A., Maris J. M., Sondel P. M., Antitumor activity of Hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study Journal of Clinical Oncology 2010 28 33 4969 4975
41. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., Thibault G., Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship Cancer Research 2004 64 13 4664 4669 (Pubitemid 38856941)
42. Koene H. R., Kleijer M., Algra J., Roos D., Von Dem Borne A. E. G. KR., De Haas M., Fc RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FC RIIIa, independently of the FC RIIIa-48L/R/H phenotype Blood 1997 90 3 1109 1114 (Pubitemid 27314146)
43. Dijstelbloem H. M., Scheepers R. H. M., Oost W. W., Stegeman C. A., Van Der Pol W. L., Sluiter W. J., Kallenberg C. G. M., Van De Winkel J. G. J., Cohen Tervaert J. W., Fc receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse Arthritis and Rheumatism 1999 42 9 1823 1827 (Pubitemid 30257745)
44. Wu J., Edberg J. C., Redecha P. B., Bansal V., Guyre P. M., Coleman K., Salmon J. E., Kimberly R. P., A novel polymorphism of Fc RIIIa (CD16) alters receptor function and predisposes to autoimmune disease Journal of Clinical Investigation 1997 100 5 1059 1070 (Pubitemid 27386289)
45. Jenkins M. R., Tsun A., Stinchcombe J. C., Griffiths G. M., The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse Immunity 2009 31 4 621 631
46. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc rIIIa gene Blood 2002 99 3 754 758 (Pubitemid 34525533)
47. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., Neri T. M., Ardizzoni A., Immunoglobulin g fragment c receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer Journal of Clinical Oncology 2008 26 11 1789 1796
48. Zhang WU., Gordon M., Schultheis A. M., Dong Y. Y., Nagashima F., Azuma M., Chang H. M., Borucka E., Lurje G., Sherrod A. E., Iqbal S., Groshen S., Lenz H. J., FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single-agent cetuximab Journal of Clinical Oncology 2007 25 24 3712 3718 (Pubitemid 47372612)
49. Weng W. K., Levy R., Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma Journal of Clinical Oncology 2003 21 21 3940 3947 (Pubitemid 46606207)
50. Jonsson A. H., Yokoyama W. M., Natural killer cell tolerance licensing and other mechanisms Advances in Immunology 2009 101 27 79
51. Vilches C., Parham P., KIR: diverse, rapidly evolving receptors of innate and adaptive immunity Annual Review of Immunology 2002 20 217 251 (Pubitemid 34293425)
52. Orr M. T., Murphy W. J., Lanier L. L., 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection Nature Immunology 2010 11 4 321 327
53. Elliott J. M., Wahle J. A., Yokoyama W. M., MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment Journal of Experimental Medicine 2010 207 10 2073 2079
54. Joncker N. T., Shifrin N., Delebecque F., Raulet D. H., Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment Journal of Experimental Medicine 2010 207 10 2065 2072
55. Leung W., Handgretinger R., Iyengar R., Turner V., Holladay M. S., Hale G. A., Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma British Journal of Cancer 2007 97 4 539 542 (Pubitemid 47258461)
56. Venstrom J. M., Zheng J., Noor N., Danis K. E., Yeh A. W., Cheung I. Y., Dupont BO., O'Reilly R. J., Cheung N. K. V., Hsu K. C., KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma Clinical Cancer Research 2009 15 23 7330 7334
57. Anfossi N., André P., Guia S., Falk C. S., Roetynck S., Stewart C. A., Breso V., Frassati C., Reviron D., Middleton D., Romagné F., Ugolini S., Vivier E., Human NK cell education by inhibitory receptors for MHC class I Immunity 2006 25 2 331 342 (Pubitemid 44224147)
58. Kiessling R., Klein E., Wigzell H., 'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype European Journal of Immunology 1975 5 2 112 117